GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SenzaGen AB (OSTO:SENZA) » Definitions » Short-Term Debt

SenzaGen AB (OSTO:SENZA) Short-Term Debt : kr0.00 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is SenzaGen AB Short-Term Debt?

SenzaGen AB's Short-Term Debt for the quarter that ended in Dec. 2024 was kr0.00 Mil.


SenzaGen AB Short-Term Debt Historical Data

The historical data trend for SenzaGen AB's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SenzaGen AB Short-Term Debt Chart

SenzaGen AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SenzaGen AB Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

SenzaGen AB Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


SenzaGen AB Short-Term Debt Related Terms

Thank you for viewing the detailed overview of SenzaGen AB's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


SenzaGen AB Business Description

Traded in Other Exchanges
N/A
Address
Scheeletorget 1, Medicon Village, Building 401, Lund, SWE, 223 81
SenzaGen AB markets sells, and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its laboratory and licensed Contract Research Organizations (CROs) in Sweden. It offers animal-free testing of chemical compounds in cosmetics, pharmaceuticals, food products, and dyes. It operates in five market segments- Cosmetics, Chemicals, Medical devices, Pharmaceuticals, and Nutrition/food additives. The majority is from the Pharmaceuticals segment. Geographically it operates in North America, Europe, APAC, and RoW, the majority is from Europe.

SenzaGen AB Headlines

No Headlines